The EUROCARE database contains data on 6.5 million cancer patients diagnosed from 1978 to 1994 in populations covered by 67 cancer registries in 22 European countries. The quality-checked entries specify age, sex, diagnosis date, cancer site, morphology, microscopic confirmation and vital status, as well as containing broad indicators of stage. For EUROCARE-3, which refers to diagnoses from 1990 to 1994, 3389 cases with major data problems and 142 525 second or subsequent cancers were removed, leaving more than 2 million cases for analysis. From these data, observed and relative survival for each cancer site and country were calculated at 1, 3 and 5 years from diagnosis. Overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures. Overall, 1.1% of cases were lost to follow-up, 4.2% were known from death certificates only and 1.2% were known at autopsy only. The percentage of microscopically confirmed cases varied with cancer site and country, and was always higher in northern European countries. Comparison of quality indicators for the EUROCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved.
The EUROCARE database
EUROCARE, which began in 1990, is a collaborative project between European cancer registries. Its purpose is to estimate and compare cancer survival in European populations. The present EUROCARE database includes incidence and life status information on cancer patients diagnosed from 1978 to 1994 and followed-up at least until the end of 1998. EUROCARE has published two major monographs: EUROCARE-1 [1] , which analysed survival in ~800 000 cancer cases incident between 1978 and 1985; and EUROCARE-2 [2] which analysed ~1 300 000 cancer patients diagnosed from 1985 to 1989. The present issue of Annals of Oncology constitutes the third major EUROCARE monograph (EUROCARE-3) and is concerned with the survival of cancer patients diagnosed in the latest available quinquennium (1990) (1991) (1992) (1993) (1994) .
This paper describes the methods used for data checking and survival analysis in EUROCARE-3. It also illustrates the most important characteristics of the database and includes an evaluation of registration and follow-up quality.
Participating registries and populations covered
Sixty-seven registries sent their incidence and follow-up data to EUROCARE-3. Eleven of these registries (Denmark, Estonia, Finland, Iceland, Malta, Norway, Slovakia, Slovenia, Scotland, Sweden and Wales) are national registries covering their entire populations. The other registries are regional registries covering from 3% to 62% of the populations of their respective countries ( Table 1 ). The proportion of the national population covered increased with respect to EUROCARE-2 for Italy (9.7-15.3%), England (49.6-62.6%) and The Netherlands (5.7-23.7%). Five countries are included in EUROCARE-3 that were not present in EUROCARE-2: the Czech Republic, Malta, Norway, Portugal and Wales.
A second German registry, the Munich cancer registry, joined EUROCARE-3 contributing data for cases diagnosed in 1993 and 1994. The relative survival of these Munich cases was very high: the highest in Europe for most cancer sites, and often higher than that observed in the USA [3] . A longer period of incidence and more stage information is necessary to determine whether the high survival in Munich is real or due to case selection-a process which is likely to occur during the early years of population-wide collection by what used to be clinical registry. Munich is therefore included in the database as an individual registry but the data were (France) . Sweden, previously represented by one regional registry, now has complete national coverage in EUROCARE.
Ten specialised childhood cancer registries participated in EUROCARE-3: Brittany, Lorraine and Rhone-Alpes (France), the Dutch Childhood Leukaemia Registry, Germany, Piedmont and Marche (Italy), the Spanish National Childhood Cancer Registries (which sent data for the province of Barcelona), Valencia (Spain) and the UK. Only four of these contributed to EURO-CARE-2 [4] . In summary, 67 cancer registries sent data on 53 general and 44 childhood populations. Social, health and cancer control characteristics of the regions covered by these cancer registries are described elsewhere [1, 2, 5] .
The cancer cases included in EUROCARE-3 were incident in a total population of 101 million, representing about a quarter of the total population of the 22 countries involved. For six registries (Munich, Sassari, Granada, South Portugal, Isère, Malta and the section of the German Childhood Cancer Registry covering former East Germany), the incidence data did not completely cover the specified incidence period (from 1990 to 1994). In contrast, >50% of registries presented cancer incidence data spanning more than 15 consecutive years.
Four registries (Granada, Isère, Murcia and South Portugal) had adequate follow-up for only a subset of cancer sites and their data were excluded from the analysis of all cancers combined. The three specialist registries of Côte d'Or were also excluded from this analysis because their registration was restricted to specific cancer sites only. Further details of the coverage for childhood cancer are given elsewhere [6] .
Data collection and standardisation
Survival data were collected on all malignant cancers as defined by codes 140-172 and 174-208 of the ninth revision of the International Classification of Diseases (ICD-9) and also for cases of non-malignant transitional cell neoplasms of the bladder. Nonmelanoma skin cancers were excluded (Table 2) .
Each participating cancer registry sent the entire set of its incidence data for which a sufficiently long follow-up was available. This dataset included cases sent to earlier EUROCARE studies in order to update vital status. The data were placed in a central database. Only first primary cancers were included in the survival analyses although data on second and subsequent primaries was retained. Data on multiple tumours is rarely available either at the clinical or population level, and the large EURO-CARE database on these tumours constitutes a valuable resource for future studies. According to international rules for ranking multiple cancers, non-malignant neoplasms and non-melanoma skin cancers are ignored as first cancers. Synchronous cancers at a single site are considered one cancer. For synchronous cancers at different sites, that with the worse prognosis is considered as the first.
Data on in-situ neoplasms were also collected, but again these were not included in the survival analyses. Since the frequency of in-situ neoplasms is related to early diagnosis activity in a population, comparative analysis of in-situ frequencies may assist the interpretation of survival differences between populations.
For bladder cancers, standardised rules for including papillomas and non-invasive carcinomas were lacking, therefore transitional cell neoplasms with non-malignant and uncertain behaviour were included among these cancers. Borderline ovarian cancers (ICD-O-2 8342, 8451, 8462, 8472, 8473) [7] were also included, although they were excluded from EUROCARE-2. These lesions were coded as malignant (fifth digit = 3) in International Classification of Diseases for Oncology, second revision (ICD-O-2), but not in previous [8] and subsequent classifications [9] .
For each case, the EUROCARE-3 study protocol required the following data: sex; month and year of birth; month and year of diagnosis; month and year of latest vital status ascertainment; vital status; tumour topography (site) code (ICD-9); morphology and behaviour code (ICD-O-2); and information on microscopic confirmation. Basic information on stage (lesion confined to organ, regional extension, distant metastasis, not available) was also supplied if available. Each registry assigned a unique identification code to each case record (that did not allow the individuals to be identified) to facilitate data quality checks.
Site was coded as ICD-7 by the Finnish registry and had to be converted to ICD-9; Slovenian data were converted from ICD-8. Morphology code conversion was necessary for the Finnish, Norwegian and some English registries, and for Slovenian cases incident before 1983. Reconstruction of ICD-O-2 morphology was achieved for almost all of these cases thanks to the active collaboration of personnel in the registries concerned. For this reason EUROCARE-3 contains a higher proportion of cases with consistent morphology codes than previous studies. For all nonsolid tumours, ICD-O to ICD-9 conversion was automatic when the morphology code was present. Some lymphomas had topography codes attributing the disease to a specific organ (extranodal lymphomas); these were recorded simply as lymphomas.
Automatic checking
Unlikely site-morphology combinations, including the standard International Agency for Research on Cancer (IARC) checks for data submitted to Cancer Incidence in Five Continents [10] , were the most frequent problem encountered by the automatic checking procedure. Records containing invalid codes, or impossible or improbable sex-age-site-morphology combinations were sent back to the registries for checking and correction if possible. Records returned after review were automatically re-checked. All records definitively included in the database had fields indicating whether the content had been changed during checking, if it had been reviewed by the registry personnel, and if any problems remained. In the latter case, the problem was categorised as 'major' when missing, invalid or inconsistent values occurred in dates, sex, site or morphology; as 'minor' when unlikely age-site-morphology combinations were confirmed; and as 'invalid behaviour' for invalid morphology/behaviour combinations. Site and morphology codes listed in ICD-9 and ICD-O-2, respectively [7, 11] , were generally the only ones considered valid by the checking procedure; however, morphology codes introduced in the third revision of the international classification [9] and not present in ICD-O-2 were also admissible. The checking procedure only accepted a behaviour code as valid if the morphology/behaviour combination was present in the ICD-O morphology list. (This contradicts rule F of the coding guidelines [9] stating that any behaviour code can be associated with any morphological type.) Missing morphology codes were accepted only for cases not verified microscopically. For microscopically verified cases, missing values were imputed as 8000/3 for malignant cancers, and as 8000/1 if malignant status was uncertain. Table 3 summarises the results of the data checking procedure for each registry. Column 4 reports the number of cases received from the registries. Column 5 shows the cases excluded immediately as non-pertinent (usually benign, non-neoplastic disease or duplicate registrations). A total of 6 552 672 records were sent to EUROCARE-3 including the 49 924 records from childhood registries. After rejecting 5010 non-pertinent general cases and 172 non-pertinent childhood cases, the database contained 6 497 638 general records and 49 752 records from childhood registries (Table 3) . Column 6 shows the total number of cases accepted in the database. This includes the 99.6% of cases that eventually passed all the quality checks (column 7), a few cases (<0.1%) accepted with invalid behaviour codes (column 8), 0.1% accepted with minor errors (column 9) and 0.2% to be excluded from survival analysis because of major errors (column 10). The latter, however, were retained in the database for possible future correction.
The validation process resulting in the above classification required further manual checking of 61 371 general and 494 childhood case records that were sent back to the registries. Two registries (South & West England and Wales) could not perform this manual checking prior to the EUROCARE-3 analysis.
Some of the cases from childhood cancer registries were also present in general cancer registry files. This occurred in registries of England and Wales, Germany, Italy and The Netherlands. In these cases, only records from childhood registries were used in the analysis of childhood cancer survival.
Cases incident 1990-1994: validity indicators and quality analysis
The characteristics of the 1990-1994 data (for adults) are summarised in Table 4 . A total of 2 202 169 cases diagnosed in this period were included in the database (after eliminating nonpertinent cases as described above). A total of 3394 records had major errors while 139 601 records pertained to multiple cancers. These cases were excluded from the survival analyses leaving 2 059 174 records of first primary cancers in adults for analysis. Among these cases, 0.7% had incomplete follow-up, 4.2% were notified to the registry via death certificate only (DCO) and 1.2% were notified via autopsy reports only.
The proportion of multiple tumours was highly variable across registries, ranging from 18% (Mersey, England) to <1% (Murcia, Spain). This suggests imperfect standardisation in the rules for classification/definition of multiple tumours. In general, registries that have been in operation for a long time, and therefore with long follow-up periods-typically northern European registries-have higher proportions of multiple cancers than registries that have been operating for less time. However, the long-established (>15 years) registries of Cracow, Trent, Slovakia and Saarland had <3% multiple tumours and this suggests lower data quality. Similarly, good information quality is suggested by a high proportion of multiple tumours in the database of registries with a short incidence period.
The study protocol stipulated that all cases should have at least 4 years of follow-up. An overall proportion of 0.7% of cases was lost to follow-up before the end of the 4-year period. This proportion was low in most registries, except for 15 registries where >1% of cases were lost, and in six of these >5% of cases. Figures for proportions lost to follow-up have little meaning if only passive follow-up methods are used (as in the Basque Country and in all UK registries except East Anglia).
Thames had the highest proportion of DCO cases (17%), followed by Slovakia (9.1%), Navarra (8.8%) and the Basque Country (7.6%). Six registries had DCO cases in the range 5-7%; while the average value was 4.2%. As noted before, overall 1.2% of cases were found only at autopsy: most registries had values close to this; the only outlier was the registry of the Czech Republic (8.7%). The proportion of deaths that occurred within 1 month was on average 7.1%, with substantially higher values in the UK and Poland. Table 5 shows the proportions of microscopically (histologically or cytologically) confirmed cases by country for selected cancer sites. Poor prognosis and difficult access cancers, such as those of the lung and digestive tract, had the lowest proportions of microscopically confirmed cases; good survival cancers, such as skin melanoma and breast cancer, had the highest proportions of microscopically confirmed diagnoses. The registries in northern Europe, The Netherlands, Switzerland, France and Munich had the highest proportions (usually >95%) of microscopically verified cases. Poland, Slovakia, most English registries, South Portugal and Ragusa had the lowest proportions (usually <90%). Table 6 shows 5-and 10-year survival, by country, for a selection of poor survival cancers (acute myeloid leukaemia, cancers of pleura, lung, pancreas, biliary tract, liver and oesophagus) as indirect indicators of follow-up quality. High survival for these cancers suggests (but does not prove) inadequate follow-up procedures. Countries rather than individual registries are listed for maximum comparability. Outlier countries are shown in bold. No country had unbelievably high survival for these sites; however, systematically better survival characterised Spain, Wales and Iceland. For Iceland, with its small population and numerically small numbers of cases, this is more likely due to random variation. For Spain and Wales, the figures suggest follow-up problems.
With the same purpose to indirectly evaluate the quality of the follow-up procedures, 5-year observed survival for stomach and colorectal cancers with metastases at diagnosis are shown in Table 7 . Because of incomplete stage information, the data are presented only for the 16 registries with stage information for at least half the cases at each site. The 5-year survival of stomach cancer cases with distant metastases at diagnosis ranged from <1% (Côte d'Or, Amsterdam, Norway, Slovenia, Varese and Warsaw) to >4% for Saarland and the Swiss registries. For colorectal cancer, the minimum was 2.6% (Estonia) and the maximum was 9% (Finland and Saarland). In a few cases, e.g. Saarland and Thames, the proportion of 5-year survivors was substantially higher than the average proportion for both stomach and colorectal metastatic cases, suggesting possible follow-up problems; however, stage information is often not available for advanced and non-operated patients. This can selectively bias relative survival figures based on staged cases only.
Statistical methods

Relative survival
Relative survival is the ratio of the observed survival in a group of patients to the survival probability estimated over the same period in a group of people in the general population of similar age and sex. The Hakulinen method was used to calculate relative survival in EUROCARE-3 [12, 13] . Theoretically, relative survival can exceed 100% if the survival of the patients is greater than the expected survival of the matched general population. This can occur for cancers with high survival probability, if patients lead a healthier life or are better treated for co-morbidities than the reference population. It can also occur by chance with small numbers of patients. In view of this, the cumulative relative survival was constrained to a range between 0 and 100%. Standard error of the estimated relative survival was obtained using Greenwood's formula [14] . Ninety-five per cent confidence intervals were constrained through a logarithmic transformation to be non-negative. The upper limit can be >1 (or >100% when expressed as a percentage).
European survival
Overall European survival estimates for each cancer site, by age, sex and time since diagnosis, were calculated as the weighted average of the survival for each country or national pool of registries. The weightings applied were the annual sex-and site-specific numbers of incident cases at national level estimated from the available registries' data. The weightings for Germany were based on incidence in former West Germany only. This was done because the only German registry used in calculating European survival estimate was Saarland (West Germany). The weightings used were not agedependent for practical and theoretical reasons (data availability, simplicity of presentation, comparability of results and stability of estimates). Assuming that the fraction of the national population covered by cancer registration in each country is representative of that of the whole country (this may not be the case, for example, in Germany), the European survival figures can be interpreted as estimates of the average relative survival of all patients diagnosed in the 22 countries considered. Standard errors of European survival were calculated from weighted averages of the corresponding variances of countryspecific survival. Confidence intervals for European survival were calculated assuming a normal distribution after log transformation; for this reason, pooled survival estimates and their confidence intervals were always positive but could be greater than 1, although this rarely happened in practice.
Age-adjusted survival
In order to be comparable between different populations, relative survival figures must be either age-specific or age-adjusted. In EUROCARE-3 relative survival tabulated by country is presented as age-adjusted survival. Ageadjusted country-specific survival was calculated by the direct method, using five age classes and, as standard, the age distribution of the whole set of cases analysed for each site. The same standard distribution was used for both sexes. European age-adjusted relative survival is computed in the same way from the corresponding age-specific European survival estimates. European ageadjusted survival figures were generally similar to non-age-adjusted figures although, in a few cases, they can substantially differ. Confidence intervals for age-adjusted relative survival were calculated assuming a normal distribution after logarithmic transformation; however, no constraint was set for the upper interval.
Missing age-specific values
Age-adjusted survival ratios cannot be computed when there are no cases in one or more age classes. This is reflected in missing age-adjusted values for many smaller countries in less frequent cancer sites. The same problem is more serious if geographical comparisons based on age-adjusted values are to be extended at the registry level. An imputation procedure has then been used to fill missing age-specific survival ratios in single cancer registries with an estimate.
A survival model with independent age (a i ), registry (r k ) and follow-up (f j ) interval categorical variables, log[-log(S ikj )] = a i + r k + f j , has been fitted to the whole set of 1990-1994 EUROCARE-3 age-specific relative survival ratios, S ik , stratified by gender and cancer site. Expected survival ratios provided by the models have been used for the imputation of age-specific ratios in those cases in which empirical survival was not available for lack of cases. In any case, age-adjusted ratios have not been calculated for the site-registry-gender combination with three or more age-specific missing values. 
Discussion
A major aim of EUROCARE is to analyse cancer survival differences between European countries; however, such comparisons may be confounded by the variable extent of cancer registration. In some countries, 100% of the population is covered by cancer registration, while in other participating countries <10% of the population is covered which may not be representative of the country as a whole. This issue has been extensively discussed elsewhere and will not be repeated here [15, 16] . Note, however, that the number of registries included in EUROCARE-3 was greater than in EUROCARE-2, and that for The Netherlands, Italy, England and Sweden, the percentage coverage of the population increased considerably, yet the overall cancer survival rankings of these four countries did not change. Three other issues pertaining to data quality must be considered when comparing survival between countries: completeness of case collection; disease definition; and quality of follow-up for vital status. Incomplete registration of incident cases affects survival estimates if the unregistered cases have different prognoses to the registered cases. Cases known only from the death certificate cannot be included in survival analyses because their date of diagnosis is not known. DCO cases may represent patients too ill to be hospitalised or to undergo biopsy; the exclusion of these short survival cases therefore tends to bias survival upwards. However, a high proportion of DCO cases may also be a sign that the registry is missing significant numbers of incident cases. These will include cured patients who will never be detected (the death certificate will not mention the cancer), so the result is an underestimate of true survival. Thus, a high proportion of DCO cases suggests a bias in survival estimates, but does not indicate the direction of that bias. In contrast, a low proportion of cases that would not be detected in the absence of a death certificate (the socalled death certificate-initiated cases) is indicative [1] of more complete registration procedures and therefore of negligible selection bias.
The possible causes and effects of lack of completeness in case registration have been extensively discussed in previous EURO-CARE publications [17] [18] [19] [20] . The overall proportion of DCO cases was lower in cases diagnosed in 1990-1994 than in earlier EURO-CARE incidence periods. In particular, most of the registries that in EUROCARE-2 had >10% of DCO cases had substantially lower percentages in EUROCARE-3. The exception was the English registry of South Thames which has reported high levels of DCO cases in all EUROCARE studies. In spite of this, relative survival in Thames (see electronic data [21] ) was comparable with that in other UK registries that had much lower levels of DCO cases. It should also be noted that some registries do not use (Sweden) or do not have access to (Dutch and French registries) death certificates. Selection bias in these registries cannot therefore be detected via this indicator.
With regard to disease definition, the high level of standardisation attained by the participating cancer registries, and the extensive checking procedures employed by EUROCARE-3, mean that extensive misclassification with respect to disease definition and coding can be ruled out for most cancers. However, for head and neck, lung, thyroid and soft tissue cancers, regional variations in sub-site or morphology mix can influence survival estimates; while for ovary, bladder and stomach cancers, the classification of borderline malignancies varies across Europe, again resulting in survival comparability problems. Finally, screening or early diagnostic activity (for breast, cervical and prostate cancers) can complicate the interpretation of inter-country differences in survival when such activities are not similar in all countries. 'High resolution' population-based studies that collect detailed information on stage are necessary to clarify the regional survival difference for such cancer sites. This issue is further discussed elsewhere in this monograph [20] . Difficulties in ascertaining the vital status of incident cases generally result in an overestimation of survival as deaths are missed. Follow-up difficulties may be due to confidentiality constraints, lack of access to death records, or, in registries performing passive follow-up only, linkage failure between death records and registry records. An estimate of the size of the likely bias due to cases erroneously considered alive in passive follow-up was provided by EUROCARE-1 [17] . The relative survival data for poor prognosis cancers presented in Tables 6 and 7 shed further light on this problem, as high survival for such cancers suggests inadequate vital status follow-up. Inadequate follow-up is likely in Spain, Austria and, for 10-year survival, in Wales. The survival data for these countries should therefore be considered as less reliable than for other registries. This analysis also suggests that for the English registries-most of which use passive follow-uplinkage procedures are adequate.
To conclude, a great effort has been devoted by all the EURO-CARE-3 participating members to achieve the greatest possible completeness and standardisation of the data (particularly topography and morphology codes). For this reason, the EUROCARE database is more than the sum of its contributing databases, and its value as a resource for cancer surveillance in Europe is considerably greater. It is expected that data quality will continue to improve as wider use is made of this valuable resource in the future. 
